ADC Therapeutics Ltd (ADCT)
NYSE:ADCT
Earnings Data
Report Date
May 11, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.2Last Year’s EPS
-0.36Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Overall the call conveyed meaningful progress: encouraging clinical signals from LOTIS-7 and LOTIS-5 lead-in, improved revenues and expense reductions, and a stronger balance sheet with runway into 2028. However, material risks remain — commercial volumes are flat, GAAP losses persist, outcomes depend on upcoming trial readouts and regulatory actions, and the competitive landscape is intensifying. The positives (clinical progress, cost cuts, financing, and clear near-term catalysts) outweigh the negatives, though execution risk remains.Company Guidance
Strong Q4 and Full-Year Net Product Revenue Growth
ZYNLONTA net product revenues were $22.3M in Q4 2025 vs $16.4M in Q4 2024 (approximately +36%) and $73.6M for full-year 2025 vs $69.3M in 2024 (approximately +6.2%), with Q4 strength driven by customer ordering variability and activation of new accounts.
Robust Clinical Data from LOTIS-7 and LOTIS-5 Lead-in
LOTIS-7 Phase Ib updated results showed a 90% best overall response rate and a 78% complete response rate across 49 efficacy-evaluable patients (minimum 6-month follow-up). LOTIS-5 safety lead-in reported an 80% overall response rate and 50% complete response rate, supporting potential competitive second-line efficacy.
Clear Near-Term Development Catalysts and Timelines
Management expects LOTIS-5 top-line PFS data in Q2 2026 (study powered for 262 events) with full results by year-end 2026 and potential sBLA/compendia activity in H1 2027; LOTIS-7 full data and publications are planned by end of 2026, and IIT indolent lymphoma data expected between end-2026 and mid-2027.
Significant Cost Reductions and Improved Operating Efficiency
Company implemented strategic reprioritization and reduced operating cost structure by ~50%. Total adjusted operating expenses were $39.4M in Q4 and $181.3M for full-year 2025, down ~15% (quarter) and ~6% (year) versus prior periods, driven primarily by lower R&D and broad expense reductions.
Improved GAAP Results and Adjustments
GAAP net loss improved to $6.4M in Q4 2025 ($0.04 per share) from $30.7M in Q4 2024, and full-year net loss improved to $142.6M in 2025 from $157.8M in 2024, reflecting catch-up adjustment gains related to the deferred royalty obligation and lower R&D spend.
Strengthened Balance Sheet and Extended Runway
Ended 2025 with $261.3M cash and equivalents (up from $250.9M at year-end 2024, ~+4.1%). Company completed a $100M PIPE in June 2025 and a $60M PIPE in October 2025 and expects cash runway at least into 2028.
Commercial Footprint and Market Position
Established ~10% share in third-line plus DLBCL as a monotherapy; field force covers ~90% of DLBCL potential; management expects incremental commercial and MSL investments prelaunch to support second-line expansion if trials succeed.
ADCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ADCT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 10, 2026 | $4.23 | $4.80 | +13.48% |
Nov 10, 2025 | $4.04 | $4.21 | +4.21% |
Aug 12, 2025 | $2.68 | $2.94 | +9.70% |
May 14, 2025 | $1.32 | $1.81 | +37.12% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does ADC Therapeutics Ltd (ADCT) report earnings?
ADC Therapeutics Ltd (ADCT) is schdueled to report earning on May 11, 2026, Before Open (Confirmed).
What is ADC Therapeutics Ltd (ADCT) earnings time?
ADC Therapeutics Ltd (ADCT) earnings time is at May 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ADCT EPS forecast?
ADCT EPS forecast for the fiscal quarter 2026 (Q1) is -0.2.